Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.